Sales

1,305.9

1,235.9

3,991.3

3,695.5

124.7

122.8

344.9

333.0

Royalty and commission income*

87.6

82.8

259.5

256.8

0.3

0.1

1.5

1.6

Total revenues

1,393.5

1,318.6

4,250.7

3,952.3

125.0

122.9

346.4

334.6

Gross margin

1,199.8

1,099.4

3,605.1

3,327.0

86.3

86.6

237.5

231.2

Marketing and selling expenses*

–345.6

–315.0

–1,046.8

–970.7

–55.5

–51.3

–175.3

–151.7

Royalty and commission expenses*

–110.4

–102.3

–340.4

–295.4

–0.3

–0.3

–1.0

–1.1

Administration expenses

–66.9

–63.8

–198.2

–196.6

–6.9

–6.3

–18.8

–18.9

Other operating expenses and income

–39.4

–58.1

–159.3

–141.0

–0.9

–2.3

–10.7

–4.2

Research and development

–279.6

–293.2

–880.2

–867.4

–5.5

–4.2

–16.4

–12.8

Operating result

209.5

123.4

551.1

423.8

16.2

21.4

12.3

39.7

Exceptional items

–

–

–

–70.0

–

–

–

–

Earnings before interest and tax (EBIT)

209.5

123.4

551.1

353.8

16.2

21.4

12.3

39.7

Net operating assets**

–

–

10,672.8

10,015.9

–

–

343.6

336.0

Segment liabilities**

–

–

–1,143.6

–1,078.2

–

–

–78.2

–76.9

Capital spending on property, plant and equipment

53.8

71.9

161.8

192.9

1.1

1.7

3.4

6.9

Investments in intangible assets

11.9

22.0

35.3

53.4

0.2

0.1

1.0

1.0

Depreciation

–194.2

–188.8

–564.5

–563.1

–2.8

–3.0

–8.8

–7.0

Impairment losses

–0.8

–0.9

–18.0

–0.9

–

–

–

–

Net cash flows from operating activities

471.7

401.3

1,046.8

920.5

8.6

11.7

10.8

34.5

Net cash flows from investing activities

–61.3

–88.1

–187.5

–239.4

–0.9

–0.1

–4.5

–5.2

Free cash flow

410.4

313.2

859.3

681.0

7.7

11.5

6.3

29.3

Underlying free cash flow

410.4

313.2

859.3

681.0

7.7

11.5

6.3

29.3

FCR in %

29.5

23.8

20.2

17.2

6.1

9.4

1.8

8.8

ROS in %

15.0

9.4

13.0

10.7

13.0

17.4

3.5

11.9

Pharmaceuticals

EUR million

Q3
2010

Q3
2009

Jan.-Sep.
2010

Jan.-Sep.
2009

Sales

1,430.6

1,358.6

4,336.2

4,028.5

Royalty and commission income*

87.8

82.9

261.0

258.4

Total revenues

1,518.4

1,441.5

4,597.1

4,286.9

Gross margin

1,286.0

1,186.0

3,842.6

3,558.3

Marketing and selling expenses*

–401.1

–366.2

–1,222.1

–1,122.5

Royalty and commission expenses*

–110.7

–102.6

–341.3

–296.5

Administration expenses

–73.7

–70.1

–217.0

–215.5

Other operating expenses and income

–40.3

–60.4

–170.0

–145.2

Research and development

–285.1

–297.4

–896.6

–880.1

Operating result

225.7

144.8

563.4

463.5

Exceptional items

–

–

–

–70.0

Earnings before interest and tax (EBIT)

225.7

144.8

563.4

393.5

Net operating assets**

–

–

11,016.4

10,351.9

Segment liabilities**

–

–

–1,221.7

–1,155.1

Capital spending on property, plant and equipment

54.9

73.6

165.2

199.7

Investments in intangible assets

12.2

22.1

36.2

54.4

Depreciation

–196.9

–191.8

–573.3

–570.1

Impairment losses

–0.8

–0.9

–18.0

–0.9

Net cash flows from operating activities

480.4

413.0

1,057.6

955.0

Net cash flows from investing activities

–62.3

–88.2

–192.0

–244.7

Free cash flow

418.1

324.8

865.6

710.3

Underlying free cash flow

418.1

324.8

865.6

710.3

FCR in %

27.5

22.5

18.8

16.6

ROS in %

14.9

10.0

12.3

10.8